AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17203620 — intervention group
Group type: EXPERIMENTAL
Intervention: Population-level screening campaigns
Number of subjects: 0
Study 12911364 — intervention group
Group type: EXPERIMENTAL
Intervention: Auscultation group
Number of subjects: 85
Study 12911364 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure group
Number of subjects: 85
Study 12911364 — intervention group
Group type: EXPERIMENTAL
Intervention: Mark group
Number of subjects: 85
Study 11125428 — intervention group
Group type: EXPERIMENTAL
Intervention: ISP+ (isolated soy protein beverage providing 42 mg. of genistein and 27 mg. of daidzein daily)
Number of subjects: 34
Study 11125428 — intervention group
Group type: EXPERIMENTAL
Intervention: ISP- (isolated soy protein beverage providing 2.1 mg. of genistein and 1.3 mg. of daidzein daily)
Number of subjects: 34
Study 11125428 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control beverage mentioned)
Number of subjects: 34
Study 9779710 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL‐3 (5 microg/kg)
Number of subjects: 185
Study 9779710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 8148678 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated asthma care
Number of subjects: 712
Study 8148678 — intervention group
Group type: COMPARATOR
Intervention: Conventional outpatient care
Number of subjects: 712
Study 2906069 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbidopa/levodopa
Number of subjects: 15
Study 2906069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 28700818 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler measurement of MCA‐PSV (MCA‐PSV Group)
Number of subjects: 71
Study 28700818 — intervention group
Group type: COMPARATOR
Intervention: Decrease in fetal Hct (fetal Hct Group)
Number of subjects: 71
Study 28700818 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 71
Study 27316335 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwifery unit
Number of subjects: 485
Study 27316335 — intervention group
Group type: COMPARATOR
Intervention: Obstetric unit
Number of subjects: 485
Study 27316335 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstetrician involved during labor
Number of subjects: 485
Study 27316335 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapartum transfer from midwifery to obstetric unit
Number of subjects: 485
Study 27316335 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative delivery
Number of subjects: 485
Study 27316335 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 485
Study 24532352 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (group-based counseling, 8 hours over a weekend)
Number of subjects: 80
Study 24532352 — intervention group
Group type: COMPARATOR
Intervention: Control (delayed treatment with written materials only)
Number of subjects: 80
Study 24532352 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (biochemical confirmation)
Number of subjects: 80
Study 23924930 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel multi-track technique using the double-coil Inoue metal wire
Number of subjects: 62
Study 23924930 — intervention group
Group type: COMPARATOR
Intervention: Conventional multi-track technique using a balloon endhole catheter and multi-track 0.035 inch stiff wire
Number of subjects: 62
Study 19637334 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg intravenous / 1.0 mg/kg subcutaneous fontolizumab
Number of subjects: 201
Study 19637334 — intervention group
Group type: EXPERIMENTAL
Intervention: Fontolizumab (all groups)
Number of subjects: 201
Study 19637334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 18838533 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight (low‐MW) concentrated barley beta‐glucan (6 grams beta‐glucan/day)
Number of subjects: 90
Study 18838533 — intervention group
Group type: EXPERIMENTAL
Intervention: High molecular weight (high‐MW) concentrated barley beta‐glucan (6 grams beta‐glucan/day)
Number of subjects: 90
Study 16649828 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (10 weeks treatment)
Number of subjects: 536
Study 16649828 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 weeks treatment)
Number of subjects: 536
Study 12599047 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-milk HIV-1 RNA levels
Number of subjects: 275
Study 12599047 — intervention group
Group type: EXPERIMENTAL
Intervention: Colostrum/early milk
Number of subjects: 275
Study 12599047 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-milk viral RNA levels
Number of subjects: 275
Study 12599047 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-milk virus load
Number of subjects: 275
Study 11321644 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic field of a GSM-standard mobile phone
Number of subjects: 8
Study 11321644 — intervention group
Group type: COMPARATOR
Intervention: Placebo experiment
Number of subjects: 8
Study 9387950 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly infusion of human alpha1-antitrypsin (alpha1-AT) at a dosage of 60 mg x kg(‐1) body weight
Number of subjects: 295
Study 9387950 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 295
Study 8187805 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra‐operative peritoneal serum application
Number of subjects: 30
Study 8187805 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 8187805 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 30
Study 3299566 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol 120 mg/day
Number of subjects: 120
Study 3299566 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol 30 mg/day
Number of subjects: 120
Study 3299566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 30566847 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone/Azathioprine/N‐Acetylcysteine
Number of subjects: 118
Study 30566847 — intervention group
Group type: COMPARATOR
Intervention: Immunosuppression (placebo arm of ACE‐IPF)
Number of subjects: 118
Study 30566847 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppression (propensity-matched University of Texas Southwestern Medical Center IPF cohort)
Number of subjects: 118
Study 27647855 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF‐β1 mAb (2-, 10-, or 50-mg monthly subcutaneous dosing for 12 months)
Number of subjects: 416
Study 27647855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 416
Study 25695180 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry capsules
Number of subjects: 0
Study 25695180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24494285 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus fire needling (Group A)
Number of subjects: 180
Study 24494285 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture only (Group B)
Number of subjects: 180
Study 24494285 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up for cured cases in Group A
Number of subjects: 180
Study 20953803 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim on day 2 (P2)
Number of subjects: 351
Study 20953803 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim on day 4 (P4)
Number of subjects: 351
Study 19723128 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% voriconazole eye drops, hourly for four doses
Number of subjects: 10
Study 19723128 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% voriconazole eye drops, four times a day for 3 days
Number of subjects: 10
Study 17545265 — intervention group
Group type: EXPERIMENTAL
Intervention: Compomer restorations
Number of subjects: 534
Study 17545265 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite restorations
Number of subjects: 534
Study 17545265 — intervention group
Group type: COMPARATOR
Intervention: Amalgam restorations
Number of subjects: 534
Study 15302194 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate delivery (n=296)
Number of subjects: 588
Study 15302194 — intervention group
Group type: COMPARATOR
Intervention: Delayed delivery (n=292)
Number of subjects: 588
Study 11476384 — intervention group
Group type: EXPERIMENTAL
Intervention: Elite skiers (n=120)
Number of subjects: 120
Study 11476384 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (n=39)
Number of subjects: 120
Study 9823827 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet (4:1 ratio), initiated and maintained after hospitalization
Number of subjects: 51
Study 7865192 — intervention group
Group type: EXPERIMENTAL
Intervention: Community placements after discharge
Number of subjects: 114
Study 2818656 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic walking
Number of subjects: 120
Study 2818656 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic aquatics
Number of subjects: 120
Study 2818656 — intervention group
Group type: COMPARATOR
Intervention: Nonaerobic range of motion (controls)
Number of subjects: 120
Study 1163927 — intervention group
Group type: EXPERIMENTAL
Intervention: New topical ophthalmic delivery systems (specific systems not detailed)
Number of subjects: 0
Study 1163927 — intervention group
Group type: COMPARATOR
Intervention: Conventional pilocarpine drops
Number of subjects: 0
Study 1163927 — intervention group
Group type: EXPERIMENTAL
Intervention: New topical ophthalmic delivery systems
Number of subjects: 0
Study 31668861 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral-pressure needleless connectors (NP-NCs)
Number of subjects: 70
Study 31668861 — intervention group
Group type: COMPARATOR
Intervention: Positive-pressure needleless connectors (PP-NCs)
Number of subjects: 70
Study 30659987 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg every 2 weeks)
Number of subjects: 504
Study 30659987 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m2 every 3 weeks)
Number of subjects: 504
Study 30659987 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 504
Study 30659987 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 504
Study 28971620 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS treatment
Number of subjects: 0
Study 28971620 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 0
Study 26237623 — intervention group
Group type: EXPERIMENTAL
Intervention: PPIA preparation
Number of subjects: 93
Study 26237623 — intervention group
Group type: COMPARATOR
Intervention: PPIA standard
Number of subjects: 93
Study 22646659 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily text message intervention (N = 8)
Number of subjects: 18
Study 22646659 — intervention group
Group type: COMPARATOR
Intervention: Weekly general health messages (N = 10)
Number of subjects: 18
Study 21069290 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sildenafil (low, medium, and high doses)
Number of subjects: 17
Study 21069290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 20019427 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental bonding agents containing calcium phosphates
Number of subjects: 0
Study 20019427 — intervention group
Group type: COMPARATOR
Intervention: Clearfil SE Bond/Bond (Control)
Number of subjects: 0
Study 16455838 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol Turbuhaler 36 microg (delivered)
Number of subjects: 78
Study 16455838 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol pressurised metered-dose inhaler 1,600 microg (metered)
Number of subjects: 78
Study 15266726 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-protective behaviors
Number of subjects: 1355
Study 11299267 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized cycle ergometer training
Number of subjects: 633
Study 9767205 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (mean daily dose of 8.1 mg)
Number of subjects: 9
Study 9767205 — intervention group
Group type: COMPARATOR
Intervention: Methadone (mean daily dose of 39.7 mg)
Number of subjects: 9
Study 9767205 — intervention group
Group type: COMPARATOR
Intervention: Slow-release morphine (mean daily dose of 400 mg)
Number of subjects: 9
Study 8842656 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nalbuphine hydrochloride 0.3 mg kg‐1 (n = 21)
Number of subjects: 60
Study 8842656 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac suppositories 12.5 mg to a dose of 1‐2 mg kg‐1 (n = 19)
Number of subjects: 60
Study 8842656 — intervention group
Group type: COMPARATOR
Intervention: No analgesia (Control group, n = 20)
Number of subjects: 60
Study 8842656 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac group
Number of subjects: 60
Study 2250501 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention engaging families or significant others in aftercare process
Number of subjects: 418
Study 2250501 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention training patients to become effective health care consumers
Number of subjects: 418
Study 7208540 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg clonidine sustained-release capsule, single oral dose, administered for 3 consecutive days
Number of subjects: 8
Study 31537833 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted lung cancer
Number of subjects: 0
Study 31537833 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted leukemia
Number of subjects: 0
Study 31537833 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted breast cancer
Number of subjects: 0
Study 31537833 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled genetic predictors of all cancers
Number of subjects: 0
Study 31537833 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted smoking-related cancers
Number of subjects: 0
Study 31537833 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted non-smoking related cancers
Number of subjects: 0
Study 27791345 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week PNF training
Number of subjects: 42
Study 27791345 — intervention group
Group type: COMPARATOR
Intervention: Control group (Low back pain educational booklet)
Number of subjects: 42
Study 26416177 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby Friendly Community Initiative (BFCI) involving regular counseling and support by trained community health workers and health professionals on maternal, infant and young child nutrition.
Number of subjects: 812
Study 26416177 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving standard care without the BFCI intervention.
Number of subjects: 812
Study 24656693 — intervention group
Group type: EXPERIMENTAL
Intervention: MeiboPatch(®) daily for three months
Number of subjects: 30
Study 24656693 — intervention group
Group type: COMPARATOR
Intervention: LipiFlow(®) single treatment
Number of subjects: 30
Study 22506791 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet intervention
Number of subjects: 107
Study 22506791 — intervention group
Group type: EXPERIMENTAL
Intervention: Group intervention
Number of subjects: 107
Study 22506791 — intervention group
Group type: COMPARATOR
Intervention: Video controls
Number of subjects: 107
Study 21510568 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300mg
Number of subjects: 200
Study 21510568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 18824662 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus Vitamin D3 (1000 mg of elemental calcium plus 400 IU of vitamin D3 daily)
Number of subjects: 36282
Study 18824662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36282
Study 16080281 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg tablets
Number of subjects: 0
Study 12457629 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg daily azithromycin
Number of subjects: 0
Study 12457629 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg daily azithromycin
Number of subjects: 0
Study 10370876 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet with red wine supplementation (240 ml/day)
Number of subjects: 42
Study 10370876 — intervention group
Group type: COMPARATOR
Intervention: High fat diet
Number of subjects: 42
Study 10370876 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat diet with red wine supplementation
Number of subjects: 42
Study 8628543 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% administered once daily
Number of subjects: 294
Study 8628543 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% administered twice daily
Number of subjects: 294
Study 8628543 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 294
Study 8628543 — intervention group
Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 294
Study 1466214 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine 0.24 mg plus morphine 8 mg (Group 2)
Number of subjects: 45
Study 1466214 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.5 mg plus pethidine 50 mg (Group 1)
Number of subjects: 45
Study 1466214 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular placebo (Group 3)
Number of subjects: 45
Study 6700284 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term group therapy (15 weekly sessions)
Number of subjects: 36
Study 6700284 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (no immediate treatment)
Number of subjects: 36
Study 31752977 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg daily for 48 weeks
Number of subjects: 91
Study 31752977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 29573807 — intervention group
Group type: EXPERIMENTAL
Intervention: YIT10347-fermented milk
Number of subjects: 100
Study 29573807 — intervention group
Group type: COMPARATOR
Intervention: Placebo fermented milk
Number of subjects: 100
Study 26416930 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal surgery
Number of subjects: 115
Study 26416930 — intervention group
Group type: COMPARATOR
Intervention: Postnatal surgery
Number of subjects: 115
Study 23609166 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer patients
Number of subjects: 24
Study 23609166 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 24
Study 21306419 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg scopolamine administered i.v.
Number of subjects: 90
Study 21306419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 19140918 — intervention group
Group type: EXPERIMENTAL
Intervention: Device-stored AF episodes
Number of subjects: 102
Study 19140918 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported AF-related symptoms
Number of subjects: 102
Study 19140918 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity and positive predictive value of symptoms to detect AF
Number of subjects: 102
Study 19140918 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of symptomatic and asymptomatic episodes
Number of subjects: 102
Study 17200266 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine (3 oral doses at approximately 1.1 x 10(7) infectious U per dose)
Number of subjects: 1312
Study 17200266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1312
Study 15070921 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol (1 mg daily) with cyclic micronized progesterone (200 mg for 10 days/month)
Number of subjects: 31
Study 15070921 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol with cyclic micronized progesterone
Number of subjects: 31
Study 11286153 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins (lipid-modifying therapy)
Number of subjects: 0
Study 11286153 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 8402457 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rate (HDR) therapy
Number of subjects: 430
Study 8402457 — intervention group
Group type: COMPARATOR
Intervention: Low-dose rate (LDR) therapy
Number of subjects: 430
Study 3485203 — intervention group
Group type: EXPERIMENTAL
Intervention: PSK (3.0 g/day) plus chemotherapy (CAPF)
Number of subjects: 7
Study 3485203 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (CAPF) alone
Number of subjects: 7
Study 30488404 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq DLTM
Number of subjects: 60
Study 30488404 — intervention group
Group type: COMPARATOR
Intervention: AWS‐200TM
Number of subjects: 60
Study 27852295 — intervention group
Group type: EXPERIMENTAL
Intervention: Op Volle Kracht (OVK 2.0) prevention program, comprising eight meetings of 60 min each.
Number of subjects: 160
Study 27852295 — intervention group
Group type: COMPARATOR
Intervention: Psycho-educational information (control condition).
Number of subjects: 160
Study 24440672 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (9 mg once daily)
Number of subjects: 92
Study 24440672 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine (3 g once daily)
Number of subjects: 92
Study 24440672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 24378101 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX regimen (oral Xeloda 1000 mg/m² twice a day on days 1-14 and intravenous oxaliplatin 130 mg/m² on day 1, repeated every 21 days)
Number of subjects: 85
Study 24378101 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (radical resection of gastric cancer)
Number of subjects: 85
Study 20881334 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound and Color Doppler imaging
Number of subjects: 15
Study 20881334 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiography
Number of subjects: 15
Study 18375270 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine at 2 mL/hr
Number of subjects: 60
Study 18375270 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine at 5 mL/hr
Number of subjects: 60
Study 18375270 — intervention group
Group type: COMPARATOR
Intervention: Saline at 5 mL/hr (placebo)
Number of subjects: 60
Study 16762040 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated) (DrotAA)
Number of subjects: 0